Functional outcomes and quality of life after AcrySof IQ Vivity intraocular lens implantation in a real-world study.
Federico Giannuzzi, Matteo Mario Carlà, Fabio Margollicci, Gaetano Di Stefano, Andrea Molle, Lorenzo Hu, Francesco Boselli, Monica Maria Pagliara, Domenico Lepore, Fernando Molle, Stanislao Rizzo
Author Information
Federico Giannuzzi: Ophthalmology Unit, Agostino Gemelli University Polyclinic, Rome, Italy.
Matteo Mario Carlà: Ophthalmology Unit, Agostino Gemelli University Polyclinic, Rome, Italy. mm.carla94@gmail.com. ORCID
Fabio Margollicci: Ophthalmology Unit, Agostino Gemelli University Polyclinic, Rome, Italy.
Gaetano Di Stefano: Ophthalmology Unit, Agostino Gemelli University Polyclinic, Rome, Italy.
Andrea Molle: Ophthalmology Unit, Agostino Gemelli University Polyclinic, Rome, Italy.
Lorenzo Hu: Ophthalmology Unit, Agostino Gemelli University Polyclinic, Rome, Italy.
Francesco Boselli: Ophthalmology Unit, Agostino Gemelli University Polyclinic, Rome, Italy.
Monica Maria Pagliara: Ophthalmology Unit, Agostino Gemelli University Polyclinic, Rome, Italy.
Domenico Lepore: Ophthalmology Unit, Agostino Gemelli University Polyclinic, Rome, Italy.
Fernando Molle: Ophthalmology Unit, Agostino Gemelli University Polyclinic, Rome, Italy.
Stanislao Rizzo: Ophthalmology Unit, Agostino Gemelli University Polyclinic, Rome, Italy.
The extended depth-of-focus AcrySof IQ Vivity intraocular lens technology offers promising features for presbyopia management, evaluated in this research in a 6 months real-world setting. Prospective interventional mono-centric study including 40 patients who underwent elective bilateral phacoemulsification. We performed one pre-operative visit (V0) and one evaluation six months post-operatively (V1), evaluating uncorrected and corrected visual acuity for near (UNVA/CNVA), intermediate (UIVA/CIVA) and far (UDVA/UCVA), slit-lamp evaluation, tomography with static pupillometry, endothelial cell count and contrast sensitivity chart. In order to assess post-operative Quality of Life, we administered the patients McAlinden's Quality of Vision test and Morlock's Patient-Reported Spectacle Independence Questionnaire. We divided eyes in with Toric-IOL and with non-Toric IOL. A total of 36 eyes received non-tonic IOL implantation, whereas 44 eyes received toric IOL implantation. There were no statistically significant disparities observed in visual outcome measures and contrast sensitivity between the toric group and the non-toric group. Furthermore, we assessed the predictive preoperative refractive astigmatism (PPRA) and residual refractive astigmatism (RRA) in both cohorts, and no statistical significance was found between the two cohorts (p = 0.08). Twenty-one (53%) patients reported total independence from their glasses at all distances. The mean difference between the predicted and measured refractive error, as calculated by spherical equivalent, was 0.09 D. AcrySof IQ Vivity is a well-tolerated and effective IOL with optimal refractive target for both distant and intermediate vision, needing slight spherical addition for the best near vision. Great questionnaire-based satisfaction was reported by the patients.
